Research programme: duocarmycin-analogue based antibody drug conjugates - Medarex

Drug Profile

Research programme: duocarmycin-analogue based antibody drug conjugates - Medarex

Alternative Names: MED-2219; MED-2220; MED-2338; MED-2339

Latest Information Update: 29 Sep 2009

Price : $50

At a glance

  • Originator Medarex
  • Class Antibodies; Monoclonal antibodies
  • Mechanism of Action Alkylating agents; DNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 29 Sep 2009 Preclinical development is ongoing in USA
  • 02 Sep 2009 Medarex has been acquired by Bristol-Myers Squibb
  • 03 Sep 2007 Data presented at the 234th American Chemical Society National Meeting (234th-ACS-2007)added to the Cancer pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top